Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III trials ... in its flagship GLP-1 agonists -- Ozempic for type 2 diabetes and Wegovy for obesity.

In 2024, the CDC released a report showing that approximately 40.3% of adults in the U.S. had obesity ... GLP-1 receptor agonists have not been linked to dermatologic adverse events in clinical ...

According to the World Health Organization, one in eight people worldwide were living with obesity ... deeming the trial a success. While competitors are developing GLP-1 agonists, the trials ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist ... a long list of candidates in clinical trials trying ...

Knee osteoarthritis (KOA) appears to be among a long list of conditions improved by glucagon-like peptide 1 receptor agonists (GLP-1 RAs), but ... like those with obesity with or without diabetes ...

The two companies describe PF-07081532 as a "next-generation" GLP-1 agonist which can be dosed orally once a day and will be tested in type 2 diabetes and obesity.

The company's GIP/GLP-1 agonist ... trials can take several years to complete, with the median follow-up period spanning four or five years. So, although the insurance coverage for obesity ...